Spots Global Cancer Trial Database for metastatic kidney cancer
Every month we try and update this database with for metastatic kidney cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma | NCT03280667 | Renal Cell Carc... Metastatic Kidn... | Pembrolizumab p... | 18 Years - | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | |
| Interleukin-2 in Metastatic Kidney Cancer | NCT01702909 | Renal Cell Canc... Kidney Cancer M... | Interleukin-2 | 18 Years - | Western Regional Medical Center | |
| Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer | NCT01355562 | Melanoma Metastatic Kidn... | Interleukin-2 (... | 18 Years - | Loma Linda University | |
| Impact on Quality of Life, Fatigue and Cognitive Function in Anti-angiogenesis in Patients With Metastatic Kidney Cancer | NCT01336231 | Metastatic Kidn... | 18 Years - | Centre Francois Baclesse | ||
| Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer | NCT01457131 | Metastatic Canc... Metastatic Mela... Metastatic Rena... | Fludarabine Cyclophosphamid... IL-12 & Ant... | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Safety Study of RAD001 to Treat Patients With Metastatic Kidney Cancer | NCT00446368 | Carcinoma, Rena... | RAD001 | 18 Years - | The Methodist Hospital Research Institute | |
| Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer | NCT00328861 | Metastatic Mela... Metastatic Kidn... | Natural Killer ... IL-2 Cyclophosphamid... Fludarabine | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer | NCT04823923 | Kidney Neoplasm | blood sampling ... | 18 Years - | Institut du Cancer de Montpellier - Val d'Aurelle | |
| CARE1 Pragmatic Clinical Trial | NCT06364631 | Metastatic Kidn... Metastatic Kidn... | Nivolumab Ipilimumab Pembrolizumab Cabozantinib Axitinib Lenvatinib | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Impact of Sunitinib Bioavailability on Toxicity and Treatment Efficacy in Patients Treated for Metastatic Renal Cancer | NCT03846128 | Metastatic Kidn... | blood sample | 18 Years - | University Hospital, Rouen | |
| Measuring Oncological Value of Exercise and Statin | NCT05796973 | Prostate Cancer Breast Cancer Kidney Cancer Ovarian Cancer Metastatic Brea... Metastatic Kidn... Metastatic Rena... Metastatic Rena... Metastatic Pros... Metastatic Pros... Metastatic Ovar... Metastatic Ovar... | Guided physical... Atorvastatin Independent exe... | 18 Years - 99 Years | Tampere University Hospital | |
| Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer | NCT00942058 | Metastatic Kidn... Metastatic Rena... | Serum and urina... | 18 Years - | Centre Hospitalier Universitaire de Saint Etienne | |
| Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma | NCT03280667 | Renal Cell Carc... Metastatic Kidn... | Pembrolizumab p... | 18 Years - | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | |
| Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer | NCT04823923 | Kidney Neoplasm | blood sampling ... | 18 Years - | Institut du Cancer de Montpellier - Val d'Aurelle | |
| BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma | NCT01034631 | Renal Cell Carc... | Everolimus BNC105P | 18 Years - | Hoosier Cancer Research Network | |
| CALM: Managing Distress in Malignant Brain Cancer | NCT06180460 | Brain Tumor Brain Metastase... Brain Cancer Metastatic Lung... Metastatic Brea... Metastatic Mela... Metastatic Colo... Metastatic Kidn... | CALM Treatment as us... | 18 Years - | Virginia Commonwealth University | |
| Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer | NCT01160445 | Metastatic Mela... Metastatic Rena... | Zanolimumab Aldesleukin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy | NCT04623502 | Kidney Cancer Renal Cell Carc... Clear Cell Carc... Urothelial Carc... Metastatic Kidn... Metastatic Urot... Papillary Renal... Chromophobe Ren... Fumarate Hydrat... Succinate Dehyd... HLRCC Hereditary Leio... | 13C-Glucose 13C-Acetate 13C-Lactate 13C-Glutamine 13C-Fructose | 18 Years - | University of Texas Southwestern Medical Center | |
| Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer | NCT00328861 | Metastatic Mela... Metastatic Kidn... | Natural Killer ... IL-2 Cyclophosphamid... Fludarabine | 18 Years - | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
